WO2006030402A3 - Dual compartment osmotic delivery device - Google Patents
Dual compartment osmotic delivery device Download PDFInfo
- Publication number
- WO2006030402A3 WO2006030402A3 PCT/IB2005/053076 IB2005053076W WO2006030402A3 WO 2006030402 A3 WO2006030402 A3 WO 2006030402A3 IB 2005053076 W IB2005053076 W IB 2005053076W WO 2006030402 A3 WO2006030402 A3 WO 2006030402A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- delivery device
- osmotic delivery
- dual compartment
- semipermeable membrane
- compartment osmotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1763DE2004 | 2004-09-17 | ||
| IN1763/DEL/2004 | 2004-09-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2006030402A2 WO2006030402A2 (en) | 2006-03-23 |
| WO2006030402A3 true WO2006030402A3 (en) | 2006-05-18 |
Family
ID=35708749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2005/053076 Ceased WO2006030402A2 (en) | 2004-09-17 | 2005-09-19 | Dual compartment osmotic delivery device |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2006030402A2 (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040253310A1 (en) | 2001-09-21 | 2004-12-16 | Gina Fischer | Morphine polymer release system |
| WO2003024429A1 (en) | 2001-09-21 | 2003-03-27 | Egalet A/S | Polymer release system |
| EP2301526B1 (en) | 2003-03-26 | 2016-03-23 | Egalet Ltd. | Morphine controlled release system |
| WO2006046114A2 (en) * | 2004-10-25 | 2006-05-04 | Ranbaxy Laboratories Limited | Osmotic dosage forms providing ascending drug release, and processes for their preparation |
| CA2687192C (en) | 2007-06-04 | 2015-11-24 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
| NZ594207A (en) | 2009-02-06 | 2013-03-28 | Egalet Ltd | Immediate release composition resistant to abuse by intake of alcohol |
| NZ603579A (en) | 2009-06-24 | 2014-02-28 | Egalet Ltd | Controlled release formulations |
| MX2014015880A (en) | 2012-07-06 | 2015-08-05 | Egalet Ltd | Abuse deterrent pharmaceutical compositions for controlled release. |
| WO2015023675A2 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| EP3169315B1 (en) | 2014-07-17 | 2020-06-24 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| CN104224756A (en) * | 2014-09-26 | 2014-12-24 | 天津市聚星康华医药科技有限公司 | Doxazosin mesylate oral instant film and preparation method thereof |
| EP3209282A4 (en) | 2014-10-20 | 2018-05-23 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| CN106727406B (en) * | 2017-01-04 | 2018-01-19 | 北京汇诚瑞祥医药技术有限公司 | A kind of controlled release composition containing Doxazosin and preparation method thereof |
| CN115025058B (en) * | 2021-02-23 | 2024-01-26 | 成都同道慧宜生物医药科技有限公司 | Zero-level sustained-release pharmaceutical and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0334465A1 (en) * | 1988-03-21 | 1989-09-27 | Alza Corporation | Dosage form for dispensing drug for human therapy |
| WO1990008536A1 (en) * | 1989-01-30 | 1990-08-09 | Alza Corporation | Dosage form for administering calcium antagonist |
| US5028434A (en) * | 1988-07-21 | 1991-07-02 | Alza Corporation | Method for administering nilvadipine for treating cardiovascular symptoms |
| US5713852A (en) * | 1995-06-07 | 1998-02-03 | Alza Corporation | Oral dosage and method for treating painful conditions of the oral cavity |
| US20040170680A1 (en) * | 2001-05-02 | 2004-09-02 | Benjamin Oshlack | Once-a-day oxycodone formulations |
-
2005
- 2005-09-19 WO PCT/IB2005/053076 patent/WO2006030402A2/en not_active Ceased
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0334465A1 (en) * | 1988-03-21 | 1989-09-27 | Alza Corporation | Dosage form for dispensing drug for human therapy |
| US5028434A (en) * | 1988-07-21 | 1991-07-02 | Alza Corporation | Method for administering nilvadipine for treating cardiovascular symptoms |
| WO1990008536A1 (en) * | 1989-01-30 | 1990-08-09 | Alza Corporation | Dosage form for administering calcium antagonist |
| US5713852A (en) * | 1995-06-07 | 1998-02-03 | Alza Corporation | Oral dosage and method for treating painful conditions of the oral cavity |
| US20040170680A1 (en) * | 2001-05-02 | 2004-09-02 | Benjamin Oshlack | Once-a-day oxycodone formulations |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006030402A2 (en) | 2006-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2006030402A3 (en) | Dual compartment osmotic delivery device | |
| DE60237372D1 (en) | MAGNETIC RETENTION SYSTEM WITH CONTROLLED MEDICINAL RELEASE | |
| WO2003028660A3 (en) | Drug delivery devices and methods | |
| WO2005044224A3 (en) | Drug delivery system based on polymer nanoshells | |
| WO2004103336A3 (en) | Drug delivery system | |
| WO2005018702A3 (en) | Active agent delivery systems including a miscible polymer blend, medical devices, and methods | |
| CA2396152A1 (en) | Osmotic device within an osmotic device | |
| ATE269709T1 (en) | SUSTAINED-RELEASE TABLET CONTAINING A BLOOD SUGAR-LOWERING ACTIVE AND AN ANTIHYPERGLYCEMIC ACTIVE | |
| WO2006101882A3 (en) | Medicament delivery formulations, devices and methods | |
| WO2000040203A3 (en) | Polymeric delivery agents and delivery agent compounds | |
| WO2008060963A3 (en) | Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer | |
| TW200719915A (en) | Flavoring of drug-containing chewing gums | |
| BRPI0514293A (en) | diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug administration | |
| WO2005048952A3 (en) | Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle | |
| WO2005027794A3 (en) | Medical devices | |
| WO2003082207A3 (en) | Volume efficient controlled release dosage form | |
| WO2002019969A3 (en) | (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents | |
| DE60211464D1 (en) | PHARMACEUTICAL FORMULATIONS WITH CONTROLLED ACTIVE INGREDIENT CONTAINING MILKY ACID POLYMER, AND THEIR PREPARATION | |
| WO2004098537A3 (en) | Activation agents on the surface of encapsulation vesicles | |
| WO2004075875A8 (en) | Dosage form having a saccharide matrix | |
| WO2005097064A3 (en) | Taste-masked drugs in rupturing multiparticulates | |
| WO2007122510A3 (en) | Asymmetric membranes for drug delivery devices | |
| WO2006017245A3 (en) | Sulfonated styrene polymers for medical articles | |
| WO2003101425A3 (en) | Therapeutic agent-containing polymeric nanoarticles | |
| WO2004034962A3 (en) | Selective cytokine inhibitory drugs for treating myelodysplastic syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |